[1]刘　星,刘思源,刘晓钰.顺铂与卡铂对骨肉瘤细胞株作用的分子机制[J].新乡医学院学报,2016,33(5):373-378.[doi:10.7683/xxyxyxb.2016.05.008]
　LIU Xing,LIU Si-yuan,LIU Xiao-yu.Molecular mechanism of cisplatin and carboplatin on osteosarcoma cell line[J].Journal of Xinxiang Medical University,2016,33(5):373-378.[doi:10.7683/xxyxyxb.2016.05.008]
点击复制

顺铂与卡铂对骨肉瘤细胞株作用的分子机制
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
33
期数:
2016年5
页码:
373-378
栏目:
基础研究
出版日期:
2016-05-05

文章信息/Info

Title:
Molecular mechanism of cisplatin and carboplatin on osteosarcoma cell line
作者:
刘　星1; 刘思源2; 刘晓钰3
(1.武警后勤学院附属医院骨科，天津　300162；2.河北医科大学第三医院骨科，河北　石家庄　050000；3.德州市人民医院肿瘤内科，山东　德州　253000)
Author(s):
LIU Xing1; LIU Si-yuan2; LIU Xiao-yu3
(1.Department of Osteology，the Affiliated Hospital of Logistic College of Chinese People′s Armed Police Forces，Tianjin 300162，China；2.Department of Osteology，the Third Hospital of Hebei Medical University，Shijiazhuang 050000，Hebei Province，China；3.Department of Oncology，the People′s Hospital of Dezhou City，Dezhou 253000，Shandong Province，China)
关键词:
顺铂; 卡铂; 骨肉瘤细胞; 流式细胞分析; 免疫印迹
Keywords:
cisplatin; carboplatin; osteosarcoma cells; flow cytometry; western blot
分类号:
R738.3
DOI:
10.7683/xxyxyxb.2016.05.008
文献标志码:
A
摘要:
目的　探讨顺铂与卡铂对骨肉瘤细胞(MG-63)作用的分子机制。方法　骨肉瘤细胞混悬液与不同浓度顺铂和卡铂分别作用24、48、72 h后，用倒置显微镜观察细胞生长情况。用噻唑蓝法测定每孔的吸光度值，制作生长曲线，并求出顺铂和卡铂的半抑制浓度（IC50）。用IC50顺铂、卡铂作用于骨肉瘤细胞24、48、72 h后用流式细胞仪进行细胞周期分析。免疫印迹技术观察细胞的增殖细胞核抗原（PCNA）、Bcl-2和Bax的表达。结果　相同浓度顺铂和卡铂作用的骨肉瘤细胞死亡数量随时间增加而增加。不同浓度顺铂和卡铂对骨肉瘤细胞分别作用24、48、72 h后，对细胞的生长均起到抑制作用，相同时间内，药物浓度越高，生长抑制作用越明显(P<0.05)。骨肉瘤细胞与IC50顺铂和卡铂作用24、48、72 h后，在细胞各期均未见明显凋亡峰，但随着时间增加，G1、S、G2期所占比例逐渐下降；顺铂和卡铂作用后不同时间点凋亡细胞所占比例比较差异均有统计学意义（P<0.05）。与对照组比较，顺铂组和卡铂组PCNA表达下降，Bax表达增加，Bcl-2表达略减少。结论　顺铂和卡铂对肿瘤细胞生长各期均有抑制作用，对于骨肉瘤细胞来说，卡铂的浓度约需25倍于顺铂才能产生相似的生长抑制效应。顺铂、卡铂与骨肉瘤细胞作用后存在凋亡现象，但是未能形成凋亡峰，这可能与铂类化合物能够对处于任何生长周期的细胞均能产生杀伤作用有关。
Abstract:
Objective　To explore the molecular mechanism of cisplatin and carboplatin on osteosarcoma cells(MG-63).Methods　The osteosarcoma cell suspension was interacted with different concentrations of cisplatin and carboplatin for 24，48，72 h；then the cell growth was observed with inverted microscope.The absorbance value of each hole was determined by methyl thiazolyl tetrazolium(MTT) method，and the growth curve based on above results was drawed，and the half maximal inhibitory concentration （IC50） of cisplatin and carboplatin was calculated.After IC50 concentrations of cisplatin，carboplatin interacted with osteosarcoma cells for 24，48，72 h，the cell cycle was analysed by flow cytometry.The expression of proliferating cell nuclear antigen(PCNA)，Bcl-2 and Bax was observed by western blot technique.Results　The number of osteosarcoma cell death increased with the increase of time of the same concentration of cisplatin and carboplatin interacted with osteosarcoma cell.The cell growth inhibition was observed after different concentration of cisplatin and carboplatin interacted with osteosarcoma cell for 24，48，72 h.At the same time point，the greater the concentration of the drug，the more obvious the growth inhibition(P<0.05).There was no obvious peaks of apoptosis in the each cell cycle phases after IC50 cisplatin and carboplatin interacted with osteosarcoma cell for 24，48，72 h；but with the increase of time，the proportion of G1，S，G2 stage cell gradually decreased；there was statistic difference of the proportion of apoptotic cells at different time after cisplatin or carboplatin interacted with osteosarcoma cell（P<0.05）.The expression of PCNA in cisplatin and carboplatin group decreased compared with control group；the expression of Bax increased compared with control group；the expression of Bcl-2 was slightly reduced.Conclusion　Cisplatin and carboplatin have inhibition role on the growth of the each period of tumor cells.For osteosarcoma cells，the concentration of carboplatin is about 25 times of cisplatin can produce similar growth inhibition effect.There are apoptosis after cisplatin and carboplatin interacted with the osteosarcoma cell，but failed to form a peak of apoptosis，which may be associated with platinum-based compounds can kill each period of cells in the cell cycle.

参考文献/References:

［1］　FUJII M.Combination therapy with molecular targeting drugs for head and neck cancer［J］.Gan Kagaku Ryoho Cancer Chemother，2008，35(5)：740-744.
［2］　NITZ A，KONTOPANTELIS E，BIELACK S，et al.Prospective evaluation of cisplatin- and carboplatin-mediated ototoxicity in paediatric and adult soft tissue and osteosarcoma patients［J］.Oncol Lett，2013，5(1)：311-315.
［3］　KADER Y A，CHEVALIER T L，EL-NAHAS T，et al.Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel and cisplatin/pemetrexed in chemotherapy-nave patients with advanced non-squamous bronchogenic carcinoma not harboring EGFR mutation［J］.Onco Targets Ther，2013(6)：803-809.
［4］　MACHAK G N，POLOTSKI B E，MELUZOVA O M，et al.Treatment of relapsed osteosarcoma.Role of chemotherapy using ifosamide and carboplatin［J］.Vopr Onkol，2010，56(2)：220-225.
［5］　KAMAT A M.Commentary on "carboplatin based induction chemotherapy for nonorgan confined bladder cancer-a reasonable alternative for cisplatin unfit patients?"［J］.Urol Oncol，2013，31(5)：716-717.
［6］　KUA V F，ISMAIL F，CHEE EE PHUA V，et al.Carboplatin/5-fluorouracil as an alternative to cisplatin/5-fluorouracil for metastatic and recurrent head and neck squamous cell carcinoma and nasopharyngeal carcinoma［J］.Asian Pac J Cancer Prev，2013，14(2)：1121-1126.
［7］　ZHOU Y，ZANG X，HUANG Z，et al.TWIST interacts with endothelin-1/endothelin A receptor signaling in osteosarcoma cell survival against cisplatin［J］.Oncol Lett，2013，5(3)：857-861.
［8］　HOU L L，XU Q J，HU G Q，et al.Synergistic antitumor effects of tanshinone II A in combination with cisplatin via apoptosis in the prostate cancer cells［J］.Acta Pharmaceutica Sinica，2013，48(5)：675-679.
［9］　ROBSON H，MEYER S，SHALET S M，et al.Platinum agents in the treatment of osteosarcoma：efficacy of cisplatin vs carboplatin in human osteosarcoma cell lines［J］.Med Pediatr Oncol，2002，39(6)：573-580.
［10］　LI X，HUANG T，JIANG G，et al.Synergistic apoptotic effect of crocin and cisplatin on osteosarcoma cells via caspase induced apoptosis［J］.Toxicol Lett，2013，221(3)：197-204.
［11］　STOJANOVIC N，URANKAR D，BROZOVIC′A，et al.Design and evaluation of biological activity of diazenecarboxamide-extended cisplatin and carboplatin analogues［J］.ACTA Chim Slov，2013，60(2)：368-374.
［12］　PARK J W，CHO J W，JOO S Y，et al.Paricalcitol prevents cisplatin-induced renal injury by suppressing apoptosis and proliferation［J］.Eur J Pharmacol，2012，683(1/2/3)：301-309.
［13］　SAKAO Y，KATO A，TSUJI T，et al.Cisplatin induces Sirt1 in association with histone deacetylation and increased Werner syndrome protein in the kidney［J］.Clin Exp Nephrol，2011，15(3)：363-372.
［14］　CHIAPPORI A A，SCHREEDER M T，MOEZI M M，et al.A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer［J］.Br J Cancer，2012，106(5)：839-845.
［15］　KORBAKIS D，SCORILAS A.Quantitative expression analysis of the apoptosis-related genes Bcl2，Bax and Bcl2L12 in gastric adenocarcinoma cells following treatment with the anticancer drugs cisplatin，etoposide and taxol［J］.Tumour Biol，2012，33(3)：865-875.
［16］　BIAGOSCH J，HUBER R M，BERGNER A.Reduced expression of Bax in small cell lung cancer cells is not sufficient to induce cisplatin-resistance［J］.Eur J Med Res，2010，15(10)：448-451.

相似文献/References:

[1]牛红蕊,袁 亮,吴随群.羟基喜树碱联合顺铂和足叶乙甙治疗中晚期非小细胞肺癌39例[J].新乡医学院学报,2002,19(05):419.
[2]赫鸿昌.异长春花碱联合顺铂治疗晚期非小细胞肺癌l7例[J].新乡医学院学报,2003,20(02):126.
[3]赫鸿昌.异长春花碱联合顺铂治疗晚期非小细胞肺癌17 例[J].新乡医学院学报,2003,20(02):126.
[4]张海君,闫卫东,邝先奎.目的从伦理学的角度来思考基因歧视产生的原因和所引起的危害，并寻求对策。方法查阅并分析近1O年的文献。结果导致基因歧视产生的理论观点是不正确的，这种现象对人类有极大的危害，人们可以通过对隐私权的保护来避免或减轻它对人类的伤害。结论 基因歧视是不公正也是不[J].新乡医学院学报,2003,20(06):428.
[5]刘　勇,张艳莉,刘　岩.培美曲塞联合顺铂治疗晚期非小细胞肺癌疗效观察[J].新乡医学院学报,2015,32(09):874.
[6]杨艳荣.培美曲塞与吉西他滨联合顺铂治疗晚期肺腺癌疗效及安全性比较[J].新乡医学院学报,2015,32(12):1103.
[7]申雅静,冯晨露,路　平.雷公藤内酯醇联合顺铂对食管鳞癌细胞ECA-109增殖的影响[J].新乡医学院学报,2016,33(10):864.[doi:10.7683/xxyxyxb.2016.10.007]
　SHEN Ya-jing,FENG Chen-lu,LU Ping.Effect of triptolide combined with cisplatin on proliferation of esophageal cancer ECA-109 cells[J].Journal of Xinxiang Medical University,2016,33(5):864.[doi:10.7683/xxyxyxb.2016.10.007]
[8]李　萍,姬白嫣,魏　娟,等.藏红花素对人宫颈癌Hela细胞顺铂耐药性的影响[J].新乡医学院学报,2021,38(5):401.[doi:10.7683/xxyxyxb.2021.05.001]
　LI Ping,JI Baiyan,WEI Juan,et al.Effect of crocin on cisplatin resistance of human cervical cancer Hela cells[J].Journal of Xinxiang Medical University,2021,38(5):401.[doi:10.7683/xxyxyxb.2021.05.001]
[9]肖琳琳,蔡丽芳.重组人血管内皮抑制素与顺铂交替灌注治疗恶性胸腹腔积液近期疗效观察[J].新乡医学院学报,2016,33(7):632.[doi:10.7683/xxyxyxb.2016.07.023]
　XIAO Lin-lin,CAI Li-fang.Short-term effect of recombinant human endostatin and cisplatin alternating perfusion in treatment of malignant pleural effusion or seroperitoneum[J].Journal of Xinxiang Medical University,2016,33(5):632.[doi:10.7683/xxyxyxb.2016.07.023]
[10]陈利娟,穆晓倩,刘　杰,等.PTEN通过磷脂酰肌醇-3-激酶/蛋白激酶B信号通路对非小细胞肺癌顺铂敏感性的影响[J].新乡医学院学报,2020,37(6):501.[doi:10.7683/xxyxyxb.2020.06.001]
　CHEN Lijuan,MU Xiaoqian,LIU Jie,et al.Effect of PTEN on the sensitivity of non-small cell lung cancer to cisplatin through the phosphatidylinositol-3-kinase/protein kinase B signaling pathway[J].Journal of Xinxiang Medical University,2020,37(5):501.[doi:10.7683/xxyxyxb.2020.06.001]

更新日期/Last Update: 2016-05-05